You are here

lymphoma

Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash

Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash

BioSpace

Gilead Sciences

Flag link:

FDA Puts Innate’s Lymphoma Trials on Partial Hold After Patient Death

FDA Puts Innate’s Lymphoma Trials on Partial Hold After Patient Death

BioSpace

Flag link:

BIO: Caribou tries to 'go where the puck is going' by taking on cell therapy rivals on home ice

BIO: Caribou tries to 'go where the puck is going' by taking on cell therapy rivals on home ice

Fierce Biotech

Caribou Biosciences

Flag link:

Affimed reveals 25% of staff were laid off in April in wake of phase 2 lymphoma fail

Affimed reveals 25% of staff were laid off in April in wake of phase 2 lymphoma fail

Fierce Biotech

Flag link:

Gilead’s Yescarta extends survival in lymphoma study

Gilead’s Yescarta extends survival in lymphoma study

BioPharma Dive

Gilead Sciences

large B-cell lymphoma

Flag link:

Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile

Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile

Fierce Biotech

clinical trials

Flag link:

Pfizer to buy Seagen in $43B cancer drug deal

Pfizer to buy Seagen in $43B cancer drug deal

BioPharma Dive

Flag link:

Cancer drug startup Cargo raises $200M to solve CAR-T relapse

Cancer drug startup Cargo raises $200M to solve CAR-T relapse

BioPharma Dive

Cargo Therapeutics

Flag link:

FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate

FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate

Endpoints

priority review

bispecific antibodies

Flag link:

FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022

FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022

BioPharma Dive

multiple sclerosis

Gilead Sciences

TG Therapeutics

Flag link:

Roche takes over development of Biogen-partnered lymphoma drug

Roche takes over development of Biogen-partnered lymphoma drug

BioPharma Dive

Flag link:

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

Fierce Pharma

Flag link:

With 70% staff gone, Nordic Nanovector board members jump ship amid 'strategic review'

With 70% staff gone, Nordic Nanovector board members jump ship amid 'strategic review'

Fierce Biotech

Nordic Nanovector

Flag link:

FDA lifts partial hold on Curis' lymphoma study — shares spike

FDA lifts partial hold on Curis' lymphoma study — shares spike

Endpoints

clinical trials

Flag link:

Legend scraps early-stage CAR-T for lymphoma 6 weeks after clinical hold lifted

Legend scraps early-stage CAR-T for lymphoma 6 weeks after clinical hold lifted

Fierce Biotech

clinical trials

Flag link:

Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

BioSpace

clinical trials

Flag link:

ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug

ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug

Fierce Pharma

Flag link:

Roche trumpets new glofitamab data in lymphoma at ASCO

Roche trumpets new glofitamab data in lymphoma at ASCO

Pharmaforum

bispecific antibodies

Flag link:

CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise

CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise

BioSpace

CRISPR Therapeutics

clinical trials

Flag link:

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

Pharmaforum

Gilead Sciences

Bristol Myers Squibb

large B-cell lymphoma

Flag link:

Pages